Stock Analiz

Astrazeneca PLC (AZN) financials: revenue, earnings and cash flow

Fiscal 2016–2025 + TTM · from SEC filings · data as of November 13, 2026

Summary

Astrazeneca’s revenue went from $23.0B in fiscal 2016 to $58.7B in fiscal 2025, growth of about 11.0% a year.

Net income in fiscal 2025 was $10.2B, a net margin of 17.4%; the highest of the period.

Over the twelve months to September 30, 2026, revenue was $62.4B and net income $11.0B.

Free cash flow was $11.8B in fiscal 2025 and positive in 10 of the 10 years shown.

Revenue, profit and cash flow by year

Revenue
2016: $23.0B162017: $22.5B172018: $22.1B182019: $24.4B192020: $26.6B202021: $37.4B212022: $44.4B222023: $45.8B232024: $54.1B242025: $58.7B25$58.7B
Net income
2016: $3.5B162017: $3.0B172018: $2.2B182019: $1.3B192020: $3.2B202021: $112M212022: $3.3B222023: $6.0B232024: $7.0B242025: $10.2B25$10.2B
Free cash flow
2016: $2.7B162017: $2.3B172018: $1.6B182019: $2.0B192020: $3.8B202021: $4.9B212022: $8.7B222023: $9.0B232024: $9.9B242025: $11.8B25$11.8B
EPS (diluted)
2016: $2.26162017: $1.94172018: $1.39182019: $0.86192020: $2.06202021: $0.07212022: $2.12222023: $3.84232024: $4.54242025: $6.5925$6.59

Income statement

Fiscal yearTTM2025202420232022202120202019201820172016
Revenue$62.4B$58.7B$54.1B$45.8B$44.4B$37.4B$26.6B$24.4B$22.1B$22.5B$23.0B
Gross profit—$48.1B$43.9B$37.5B$32.0B$25.0B$21.3B$19.5B$17.2B$18.1B$18.9B
Operating income—$13.7B$10.0B$8.2B$3.8B$1.1B$5.2B$2.9B$3.4B$3.7B$4.9B
Net income$11.0B$10.2B$7.0B$6.0B$3.3B$112M$3.2B$1.3B$2.2B$3.0B$3.5B
EPS (diluted)$7.06$6.59$4.54$3.84$2.12$0.07$2.06$0.86$1.39$1.94$2.26
R&D———————————
Revenue growth—+8.6%+18.0%+3.3%+18.5%+40.6%+9.2%+10.4%−1.7%−2.3%−6.9%

Cash flow

Fiscal yearTTM2025202420232022202120202019201820172016
Operating cash flow$13.2B$14.6B$11.9B$10.3B$9.8B$6.0B$4.8B$3.0B$2.6B$3.6B$4.1B
Capital spending-$7.1B-$2.8B-$1.9B-$1.4B-$1.1B-$1.1B-$961M-$979M-$1.0B-$1.3B-$1.4B
Free cash flow$6.1B$11.8B$9.9B$9.0B$8.7B$4.9B$3.8B$2.0B$1.6B$2.3B$2.7B
Dividends paid$5.0B$5.0B$4.6B$4.5B$4.4B$3.9B$3.6B$3.6B$3.5B$3.5B$3.6B
Buybacks—$521M$81M——$149M—————
Stock-based pay—$719M$660M$579M$619M$615M$277M$259M$219M$220M$241M

Balance sheet

Fiscal yearTTM2025202420232022202120202019201820172016
Cash—$5.7B$5.7B$6.0B$6.4B$6.4B$8.0B$6.2B$5.7B$4.6B$5.9B
Debt—$29.6B$30.3B$28.6B$29.2B$30.8B$20.4B$18.2B$19.1B$17.8B$16.8B
Equity—$48.7B$40.8B$39.1B$37.0B$39.3B$15.6B$13.1B$12.5B$15.0B$14.9B
Total assets—$114.1B$104.0B$101.1B$96.5B$105.4B$66.7B$61.4B$60.7B$63.4B$62.5B
Shares (diluted)1.56B1.55B1.55B1.55B1.55B1.55B1.55B1.55B1.55B1.55B1.55B

Margins and returns

Fiscal yearTTM2025202420232022202120202019201820172016
Gross margin—81.9%81.1%82.0%72.1%66.8%80.1%79.8%77.7%80.8%82.1%
Operating margin—23.4%18.5%17.9%8.5%2.8%19.4%12.0%15.3%16.4%21.3%
Net margin17.7%17.4%13.0%13.0%7.4%0.3%12.0%5.5%9.8%13.4%15.2%
FCF margin9.8%20.0%18.4%19.6%19.7%13.0%14.4%8.2%7.1%10.0%11.7%
ROIC—14.5%11.4%10.4%4.5%1.2%11.5%7.4%8.5%8.9%14.8%
ROE—21.0%17.2%15.2%8.9%0.3%20.5%10.2%17.3%20.1%23.6%

Frequently asked questions

What is Astrazeneca’s annual revenue?

$58.7B in fiscal 2025 and $62.4B over the twelve months to September 30, 2026.

How much profit does Astrazeneca make?

Net income was $10.2B in fiscal 2025 (net margin 17.4%).

Is Astrazeneca’s revenue growing?

Yes: revenue rose 8.6% in fiscal 2025 compared with the year before.

From the company’s 10-K and 10-Q filings with the SEC; per-share figures adjusted for stock splits. Rebuilt daily. Not investment advice.